Amcor heads into its September-quarter report with a story that finally looks like it is working, and a stock that has not fully believed it. Last quarter brought the first positive volume print in a year, synergies ahead of plan and a fresh promise of double-digit earnings growth in calendar 2027. Yet the shares have slipped 3.8% since that report, trailing a 1.2% decline in the S&P 500. The upcoming release, due after the close on November 4, is the first real check on whether the inflection was a turning point or a single good quarter.
The Street is looking for adjusted earnings of $0.96 a share on revenue of about $5.83 billion. The headline year-over-year EPS growth figure of roughly 405% is not a useful gauge, since the year-ago comparison of $0.19 reflects a very different, deal-distorted base. Revenue growth of about 1.5% is the more honest signal: modest, and consistent with a business that has shed five non-core operations while integrating Berry. The sequential step down from $1.23 and $6.40 billion largely reflects seasonality and those divestitures rather than deterioration. The earnings whisper sits a touch higher at $0.99, a small premium suggesting some appetite for an upside surprise but not an aggressive bar.
The more interesting comparison is with management's guide of $1.80 to $1.90 for the six-month transition period ending in December. Consensus of $0.96 for the first half of that window is slightly above an even split of the midpoint, implying the Street expects a solid start or a softer December quarter. That guide already absorbs a $0.10 to $0.12 drag from higher interest and taxes, so a clean beat here would need to come from operations, not below-the-line help.
Volumes are the first test. Flexibles rose about 1% and rigid packaging about 0.5% in the June quarter, a roughly 200 basis point swing after three straight quarters of declines, and the CFO said July held that pace. A September quarter that stays positive across regions would validate the turn; a slide back toward flat or negative would suggest the improvement was more comparison than demand. Healthcare deserves a look too, since softer lower-margin subcategories were masked by richer pharma mix. Synergies are the second pillar. Amcor delivered $285 million in its first year, about 10% ahead of plan, and growth synergy wins climbed every quarter to roughly $140 million, half the three-year target. Continued progress there, alongside margins holding near the improved levels seen last quarter despite ongoing input cost pass-through, would support the 2027 framework.
Cash is the soft spot. Free cash flow of $1.3 billion for fiscal 2026 missed a range that had already been cut once, with Middle East disruption tying up about $500 million in working capital, mostly receivables. Management called this timing and targeted more than $500 million of recovery over twelve months. Early evidence of receivables unwinding would go a long way toward restoring credibility on cash and the path to roughly 3x leverage.
Sentiment has warmed noticeably, with bullish readings rising to about 48% from 27% ahead of last quarter, and the stock trades comfortably above its 200-day average near $42.93, though about 6% below its post-earnings high of $48.94. The bar is higher than it was, but not lofty. The verdict will hinge on whether positive volumes persist and working capital starts flowing back; deliver both, and the double-digit 2027 story gains real footing.